EACS 2025 Opens in Paris: An Exclusive Interview with EACS President Prof. Milosz Parczewski
The 20th European AIDS Clinical Society (EACS) Conference (EACS 2025) officially commenced on October 15, 2025, in Paris, France. Under the theme "From Science to Implementation," the conference aims to…
A New Breakthrough in Urothelial Carcinoma Treatment — Professor Dingwei Ye from Fudan University Cancer Hospital Leads a Groundbreaking Clinical Study
Approximately 5% of urothelial carcinoma (UC) patients present with distant metastasis at diagnosis, and 30% of early-stage patients relapse or develop metastasis despite active treatment. With the emergence of antibody-drug conjugates (ADCs), the median survival of advanced UC patients has extended to 31.5 months. However, the overall survival remains suboptimal. To address this challenge, Professor Dingwei Ye and his team at Fudan University Cancer Hospital initiated a phase II clinical trial of BL-B01D1 for locally advanced or metastatic UC in 2023. The study was presented orally at the 2024 European Society for Medical Oncology (ESMO) Congress, and recently published in the Journal of Clinical Oncology (JCO, IF 41.6).
ESMO 2025丨An Academic Feast Awaits — Highlights from the Uro-Oncology Field You Won’t Want to Miss!
At the highly anticipated ESMO Congress, a wealth of cutting-edge advances will be presented, with uro-oncology standing out as one of the most vibrant and fast-evolving fields. This year, 22 Late-Breaking Abstracts (LBAs) will be showcased, accounting for nearly half of all oral presentations (45 in total) within the uro-oncology track — a testament to the field’s dynamic research momentum and strong clinical relevance.Oncology Frontier – Urology Frontier has carefully selected ten key studies and invited leading Chinese experts to share their insights and expectations.
ISEH 2025 | Professor Toshio Suda on the Core Highlights of the Conference and the Frontiers of Hematopoietic Stem Cell Research
The 54th Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH 2025) was held from September 24–27, 2025, in Kumamoto, Japan. As one of the most prestigious international conferences in the field of hematology, this year’s meeting gathered leading experts from around the world to engage in in-depth discussions on the latest advances in basic hematology, immunology, stem cell research, and cell and gene therapy. During the conference, Oncology Frontier – Hematology Frontier had the privilege of interviewing Professor Toshio Suda, former President of ISEH and Distinguished Professor at Peking Union Medical College, who shared his insights on the major highlights of the meeting and the latest developments in stem cell research.
iwCLL 2025 | Dr. Alba Garrote-de-Barros: Clinical and Biological Implications of MYC Overexpression in CLL With or Without TP53 Dysfunction
Editor’s Note: The 21st International Workshop on Chronic Lymphocytic Leukemia (iwCLL 2025) was held from September 12–15, 2025, in Kraków, Poland. As the premier global academic event dedicated to chronic…
ISEH 2025 | Professor Fumio Arai: Regulatory Mechanisms of Hematopoietic Stem Cell Quiescence and Their Clinical Translation Prospects
The 54th Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH 2025) was held from September 24–27, 2025, in Kumamoto, Japan, bringing together leading global experts in hematology to discuss cutting-edge advances in basic hematology, immunology, stem cell research, and cell and gene therapy. One of the major highlights of the event was the Sino-Japanese Joint Symposium on Stem Cells and Cellular Therapy, which drew wide attention. At the symposium, Professor Fumio Arai from Kyushu University, Japan, delivered an insightful presentation titled “Signaling networks governing hematopoietic stem cell quiescence.” In this interview, Oncology Frontier – Hematology Frontier invited Professor Arai to discuss the role of signaling networks in maintaining stem cell function and their potential in clinical applications.
Professor Xu Danfeng: Moving Beyond the “One-Size-Fits-All” Approach — Achieving Maximal Nephron Preservation for Hilar Renal Tumors Through TAPD Technology and Personalized Suturing — The Chinese Solution | 2025 Pujiang Uro-Oncology Academic Conference
Editor’s Note:In recent years, new diagnostic and therapeutic innovations in renal cancer have continued to emerge, providing clinicians with a growing range of treatment options. The widespread adoption of robot-assisted partial nephrectomy (RAPN) has enabled patients to achieve both oncological control and functional preservation. During the 2025 Pujiang Uro-Oncology Academic Conference, leading domestic and international experts in uro-oncology gathered to explore cutting-edge advances and surgical innovations in renal cancer. In this interview, Professor Xu Danfeng from Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, shares insights from his team’s pioneering surgical concepts and techniques for managing complex hilar renal tumors, offering valuable perspectives for peers in the field.
Professor Wei Qiang: Advancing Innovation Across the Entire Continuum of Uro-Oncology Care and Making Robots Trusted Surgical Partners | 2025 Pujiang Uro-Oncology Academic Conference
The 2025 Pujiang Uro-Oncology Academic Conference was successfully held in Shanghai on August 22–23, 2025. Centered on the theme “Precision Breakthroughs · Integrated Innovation · Optimized Continuum of Care,” the conference brought together numerous domestic and international experts to explore innovation in uro-oncology diagnosis and treatment, multidisciplinary collaboration (MDT), and translational research. Oncology Frontier – Urology Frontier interviewed Professor Wei Qiang of West China Hospital, Sichuan University, a member of the conference presidium, to discuss the highlights and driving impact of the event, as well as new advances in robotic surgery for urological tumors.
Any level of alcohol can be harmful for MASLD patients
A recent study by Prof. Wai-Kay Seto (The University of Hong Kong) and Prof. Jie Li (Drum Tower Hospital, Nanjing University Medical School), published in Alimentary Pharmacology & Therapeutics, systematically reviewed the epidemiology, pathogenic mechanisms, and prognostic impact of alcohol use in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), showing that alcohol consumption significantly complicates disease progression and prognosis.